

amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Inherited Disease Research Access Committee.

Date: May 10, 2024.

Time: 1:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Radisson Plaza Lord Baltimore, 20 West Baltimore Street, Hanover, Suite B, Baltimore, MD 21201 (Hybrid Meeting).

Contact Person: Barbara J. Thomas, Ph.D., Scientific Review Officer, Scientific Review Branch, National Human Genome Research Institute, National Institutes of Health, 6700B Rockledge Drive, MSC 6908, Bethesda, MD 20892, 301-402-0838, barbara.thomas@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS)

Dated: March 20, 2024.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024-06240 Filed 3-22-24; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Submission for OMB Review; 30-Day Comment Request; Cancer Therapy Evaluation Program (CTEP) Branch and Support Contracts Forms and Surveys (NCI); Correction

AGENCY: National Institutes of Health, HHS.

ACTION: Notice; correction.

SUMMARY: In compliance with the requirement of the Paperwork Reduction Act of 1995, the National Cancer Institute (NCI) has submitted to the Office of Management and Budget

(OMB) a request for review and approval of the information collection listed below.

DATES: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.

ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to <https://www.reginfo.gov/public/do/PRAMain>. Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or using the search function.

FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data collection plans and instruments, submit comments in writing, or request more information on the proposed project, contact: Michael Montello, Cancer Therapy Evaluation Program—DCTD, National Cancer Institute, 9609 Medical Center Drive, Rockville, Maryland 20850 or call non-toll-free number (240) 276-6080 or email your request, including your address to: montellom@mail.nih.gov. Formal requests for additional plans and instruments must be requested in writing.

SUPPLEMENTARY INFORMATION: This proposed information collection was previously published in the **Federal Register** on March 8, 2024, page 16776 (89 FR 16776) and allowed 60 days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment. The National Cancer Institute (NCI), National Institutes of Health, may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number.

In compliance with section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below.

Proposed Collection Title: Cancer Therapy Evaluation Program (CTEP) Branch and Support Contracts Forms and Surveys (NCI), 0925-0753, Expiration Date 03/31/2026, REVISION, National Cancer Institute (NCI), National Institutes of Health (NIH).

Need and Use of Information

Collection: This is a request for OMB to approve the revised information collection, Cancer Therapy Evaluation Program (CTEP) Support Contracts Forms and Survey. It includes modifications to OMB-approved forms for the CTSU and CIRB and the addition of new forms for the CTSU, CIRB, and CTEP. The National Cancer Institute (NCI) CTEP and the Division of Cancer Prevention (DCP) fund an extensive national program of cancer research, sponsoring clinical trials in cancer prevention, symptom management, and treatment for qualified clinical investigators. As part of this effort, CTEP implements programs to register clinical site investigators and clinical site staff and to oversee the conduct of research at the clinical sites. CTEP and DCP also oversee two support programs, the NCI Central Institutional Review Board (CIRB) and the Cancer Trial Support Unit (CTSU). The combined systems and processes for initiating and managing clinical trials are termed the Clinical Oncology Research Enterprise (CORE) and represent an integrated set of information systems and processes that support investigator registration, trial oversight, patient enrollment, and clinical data collection. The information collected is required to ensure compliance with applicable federal regulations governing the conduct of human subjects' research (45 CFR 46 and 21 CFR 50), and when CTEP acts as the Investigational New Drug (IND) holder (Food and Drug Administration (FDA) regulations pertaining to the sponsor of clinical trials and the selection of qualified investigators under 21 CFR 312.53). Survey collections assess satisfaction and provide feedback to guide improvements with processes and technology.

OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 162,836 hours.

ESTIMATED ANNUALIZED BURDEN HOURS

Form name	Type of respondent	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total annual burden hours
CTSU IRB/Regulatory Approval Transmittal Form (Attachment A01).	Health Care Practitioner	2,444	12	2/60	978
CTSU IRB Certification Form (Attachment A02) ..	Health Care Practitioner	2,444	12	10/60	4,888
Withdrawal from Protocol Participation Form (Attachment A03).	Health Care Practitioner	279	1	10/60	47
Site Addition Form (Attachment A04)	Health Care Practitioner	80	12	10/60	160
CTSU Request for Clinical Brochure (Attachment A06).	Health Care Practitioner	360	1	10/60	60
CTSU Supply Request Form (Attachment A07) ..	Health Care Practitioner	90	12	10/60	180
RTOG 0834 CTSU Data Transmittal Form (Attachment A10).	Health Care Practitioner	30	2	5/60	5
CTSU Patient Enrollment Transmittal Form (Attachment A15).	Health Care Practitioner	12	12	10/60	24
CTSU Transfer Form (Attachment A16)	Health Care Practitioner	360	2	10/60	120
CTSU OPEN Rave Request Form (Attachment A18).	Health Care Practitioner	30	21	10/60	105
CTSU LPO Form Creation (Attachment A19)	Health Care Practitioner	5	2	120/60	20
CTSU Site Form Creation and PDF (Attachment A20).	Health Care Practitioner	400	10	30/60	2,000
CTSU PDF Signature Form (Attachment A21)	Health Care Practitioner	400	10	10/60	667
CTSU CLASS Course Setup Request Form (Attachment A22).	Health Care Practitioner	10	2	20/60	7
CTSU LPO Approval of Early Closure Form (Attachment A23).	Health Care Practitioner	2,444	6	20/60	4,888
International DTL Signing (Attachment 24)	Health Care Practitioner	29	1	10/60	5
NCI CIRB AA & DOR between the NCI CIRB and Signatory Institution (Attachment B01).	Participants	50	1	15/60	13
NCI CIRB Signatory Enrollment Form (Attachment B02).	Participants	50	1	15/60	13
CIRB Board Member Application (Attachment B03).	Board Member	100	1	30/60	50
CIRB Member COI Screening Worksheet (Attachment B08).	Board Members	100	1	15/60	25
CIRB COI Screening for CIRB meetings (Attachment B09).	Board Members	72	1	15/60	18
CIRB IR Application (Attachment B10)	Health Care Practitioner	80	1	60/60	80
CIRB IR Application for Exempt Studies (Attachment B11).	Health Care Practitioner	4	1	30/60	2
CIRB Amendment Review Application (Attachment B12).	Health Care Practitioner	400	1	15/60	100
CIRB Ancillary Studies Application (Attachment B13).	Health Care Practitioner	1	1	60/60	1
CIRB Continuing Review Application (Attachment B14).	Health Care Practitioner	400	1	15/60	100
Adult IR of Cooperative Group Protocol (Attachment B15).	Board Members	65	1	180/60	195
Pediatric IR of Cooperative Group Protocol (Attachment B16).	Board Members	15	1	180/60	45
Adult Continuing Review of Cooperative Group Protocol (Attachment B17) Protocol.	Board Members	275	1	60/60	275
Adult Amendment of Cooperative Group Protocol (Attachment B19).	Board Members	40	1	120/60	80
Pediatric Amendment of Cooperative Group Protocol (Attachment B20).	Board Members	25	1	120/60	50
Pharmacist's Review of a Cooperative Group Study (Attachment B21).	Board Members	50	1	120/60	100
Adult Expedited Amendment Review (Attachment B23).	Board Members	348	1	30/60	174
Pediatric Expedited Amendment Review (Attachment B24).	Board Members	140	1	30/60	70
Adult Expedited Continuing Review (Attachment B25).	Board Members	140	1	30/60	70
Pediatric Expedited Continuing Review (Attachment B26).	Board Members	36	1	30/60	18
Adult Cooperative Group Response to CIRB Review (Attachment B27).	Health Care Practitioner	30	1	60/60	30
Pediatric Cooperative Group Response to CIRB Review (Attachment B28).	Health Care Practitioner	5	1	60/60	5

ESTIMATED ANNUALIZED BURDEN HOURS—Continued

Form name	Type of respondent	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total annual burden hours
Adult Expedited Study Chair Response to Required Modifications (Attachment B29).	Board Members	40	1	30/60	20
Reviewer Worksheet—Determination of UP or SCN (Attachment B31).	Board Members	400	1	10/60	67
Reviewer Worksheet—CIRB Statistical Reviewer Form (Attachment B32).	Board Members	100	1	15/60	25
CIRB Application for Translated Documents (Attachment B33).	Health Care Practitioner	100	1	30/60	50
Reviewer Worksheet of Translated Documents (Attachment B34).	Board Members	100	1	15/60	25
Reviewer Worksheet of Recruitment Material (Attachment B35).	Board Members	20	1	15/60	5
Reviewer Worksheet Expedited Study Closure Review (Attachment B36).	Board Members	20	1	15/60	5
Reviewer Worksheet of Expedited IR (Attachment B38).	Board Members	5	1	30/60	3
Annual Signatory Institution Worksheet About Local Context (Attachment B40).	Health Care Practitioner	400	1	40/60	267
Annual Principal Investigator Worksheet About Local Context (Attachment B41).	Health Care Practitioner	1,800	1	20/60	600
Study-Specific Worksheet About Local Context (Attachment B42).	Health Care Practitioner	4,800	1	15/60	1,200
Study Closure or Transfer of Study Review Responsibility (Attachment B43).	Health Care Practitioner	1,680	1	15/60	420
Unanticipated Problem or Serious or Continuing Noncompliance Reporting Form (Attachment B44).	Health Care Practitioner	360	1	20/60	120
Change of Signatory Institution PI Form (Attachment B45).	Health Care Practitioner	120	1	20/60	40
Request Waiver of Assent Form (Attachment B46).	Health Care Practitioner	35	1	20/60	12
CIRB Waiver of Consent Request Supplemental Form (Attachment B47).	Health Care Practitioner	20	1	15/60	5
Review Worksheet CIRB Review for Inclusion of Incarcerated Participants (Attachment B48).	Board Members	20	1	60/60	20
Notification of Incarcerated Participant Form (Attachment B49).	Health Care Practitioner	20	1	20/60	7
Final Video Submission Posting Form (Attachment B50).	Health Care Practitioner	80	1	15/60	20
Unanticipated Problem or Serious or Continuing Noncompliance Application (Attachment B52).	Health Care Practitioner	20	1	30/60	10
CIRB Customer Satisfaction Survey (Attachment C04).	Participants	600	1	15/60	150
Follow-up Survey (Communication Audit) (Attachment C05).	Participants/Board Members.	300	1	15/60	75
CIRB Board Member Annual Assessment Survey (Attachment C07).	Board Members	60	1	15/60	15
PIO Customer Satisfaction Survey (Attachment C08).	Health Care Practitioner	60	1	5/60	5
Audit Scheduling Form (Attachment D01)	Health Care Practitioner	229	5	21/60	401
Preliminary Audit Finding Form (Attachment D02)	Health Care Practitioner	229	5	10/60	191
Audit Maintenance Form (Attachment D03)	Health Care Practitioner	158	5	9/60	119
Final Audit finding Report Form (Attachment D04).	Health Care Practitioner	110	11	1,098/60	22,143
Follow-up Form (Attachment D05)	Health Care Practitioner	44	7	27/60	139
Roster Maintenance Form (Attachment D06)	Health Care Practitioner	7	1	18/60	2
Final Report and CAPA Request Form (Attachment D07).	Health Care Practitioner	3	9	1,800/60	810
NCI/DCTD/CTEP FDA Form 1572 for Annual Submission (Attachment E01).	Physician	26,500	1	15/60	6,625
NCI/DCTD/CTE Biosketch (Attachment E02)	Physician; Health Care Practitioner.	48,000	1	120/60	96,000
NCI/DCTD/CTEP Financial Disclosure Form (Attachment E03).	Physician; Health Care Practitioner.	48,000	1	15/60	12,000
NCI/DCTD/CTEP Agent Shipment Form (ASF) (Attachment E04).	Physician	24,000	1	10/60	4,000
NINT Registration Form?	Health Care Practitioner, Other.	1,000	1	60/60	1,000
ISS Form	Physician	2,100	1	15/60	525

ESTIMATED ANNUALIZED BURDEN HOURS—Continued

Form name	Type of respondent	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total annual burden hours
Basic Study Information Form (Attachment TBD)	Health Care Practitioner	140	1	20/60	47
Totals	173,523	253,570	162,836

Dated: March 20, 2024.

Diane Kreinbrink,

Project Clearance Liaison, National Cancer Institute, National Institutes of Health.

[FR Doc. 2024–06233 Filed 3–22–24; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Aging; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual grant applications conducted by the National Institute On Aging, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Board of Scientific Counselors, NIA Board of Scientific Council, NIA.

Date: May 29–31, 2024.

Closed: May 29, 2024, 8:00 a.m. to 8:45 a.m.

Agenda: To review and evaluate executive Session; Opening Remarks, (Richard J. Hodes, M.D., NIA Director, and Luigi Ferrucci, M.D., Ph.D., Scientific Director, NIA); Board Business, (Andrea LaCroix, Ph.D., Chairperson, and Holly M. Brown-Borg, Ph.D., Incoming Chairperson).

Place: National Institute on Aging, Biomedical Research Center, 3C211/Virtual, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

Open: May 29, 2024, 8:45 a.m. to 9:45 a.m.

Agenda: Bias in the Review Process

Presentation (Marie Bernard, M.D., Chief Officer for Scientific Workforce Diversity, NIH).

Place: National Institute on Aging, Biomedical Research Center, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

Open: May 29, 2024, 9:45 a.m. to 10:00 a.m.

Agenda: Break.

Place: National Institute on Aging, Biomedical Research Center, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

Open: May 29, 2024, 10:00 a.m. to 10:15 a.m.

Agenda: LBN Overview (Susan Resnick, Ph.D., Laboratory Chief, Senior Investigator, LBN).

Place: National Institute on Aging, Biomedical Research Center, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

Open: May 29, 2024, 10:15 a.m. to 10:30 a.m.

Agenda: Discussion.

Place: National Institute on Aging, Biomedical Research Center, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

Open: May 29, 2024, 10:30 a.m. to 11:00 a.m.

Agenda: A historical perspective on BABS brain and cognitive aging studies: Setting the stage for the future (Susan Resnick, Ph.D., Laboratory Chief, Senior Investigator, LBN).

Place: National Institute on Aging, Biomedical Research Center, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

Open: May 29, 2024, 11:00 a.m. to 11:30 a.m.

Agenda: Discussion.

Place: National Institute on Aging, Biomedical Research Center, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

Closed: May 29, 2024, 11:30 a.m. to 11:45 a.m.

Agenda: To review and evaluate Dr. Resnick meets individually and privately with BSC members.

Place: National Institute on Aging, Biomedical Research Center, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

Open: May 29, 2024, 11:45 a.m. to 12:00 p.m.

Agenda: Break.

Place: National Institute on Aging, Biomedical Research Center, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

Closed: May 29, 2024, 12:00 p.m. to 1:30 p.m.

Agenda: To review and evaluate executive Session Luncheon.

Place: National Institute on Aging, Biomedical Research Center, 3A519/Virtual,

251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

Open: May 29, 2024, 1:30 p.m. to 2:00 p.m.

Agenda: Integrating omics and neuroimaging to identify ADRD risk factors, biomarkers, and therapeutic targets (Keenan Walker, Ph.D., NIH Distinguished Scholar, Tenure-Track Investigator, LBN).

Place: National Institute on Aging, Biomedical Research Center, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

Open: May 29, 2024, 2:00 p.m. to 2:30 p.m.

Agenda: Discussion.

Place: National Institute on Aging, Biomedical Research Center, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

Open: May 29, 2024, 2:30 p.m. to 3:00 p.m.

Agenda: Target discovery, preclinical validation, and clinical translation of novel Alzheimer's therapies (Madhav Thambisetty, M.D., Ph.D., Senior Investigator (Clinical), LBN).

Place: National Institute on Aging, Biomedical Research Center, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

Open: May 29, 2024, 3:00 p.m. to 3:30 p.m.

Agenda: Discussion.

Place: National Institute on Aging, Biomedical Research Center, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

Open: May 29, 2024, 3:30 p.m. to 3:45 p.m.

Agenda: Break.

Place: National Institute on Aging, Biomedical Research Center, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

Open: May 29, 2024, 3:45 p.m. to 4:00 p.m.

Agenda: Drs. Walker and Thambisetty meet individually and privately with BSC members.

Place: National Institute on Aging, Biomedical Research Center, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

Closed: May 29, 2024, 4:00 p.m. to 5:30 p.m.

Agenda: To review and evaluate executive Session (Biomedical Research Center, 3rd Floor, Room 3C211/Virtual).

Place: National Institute on Aging, Biomedical Research Center, 3C211/Virtual, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

Closed: May 29, 2024, 5:30 p.m. to 5:30 p.m.

Agenda: To review and evaluate adjourn.

Place: National Institute on Aging, Biomedical Research Center, 3C211/Virtual, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

Closed: May 30, 2024, 8:00 a.m. to 8:30 a.m.

Agenda: To review and evaluate executive Session—Opening Remarks, (Richard J. Hodes, M.D., NIA Director, and Luigi Ferrucci, M.D., Ph.D., Scientific Director,